Effect of bioadhesion on initial in vitro buoyancy of effervescent floating matrix tablets of ciprofloxacin HCL

Jeetendra Singh Negi, Abhinav Trivedi, Praveen Khanduri, Vandana Negi, Nikhil Kasliwal
Department of Pharmaceutical Sciences, Sardar Bhagwan Singh PG Institute of Biomedical Sciences and Research, Balawala, Dehradun, Uttarakhand, Product Development & Research (Formulation and Development), Jubilant LifeSciences, Noida, Delhi, India

Abstract
The purpose of this study was to investigate effect of bioadhesion on the initial in vitro buoyancy behaviour of effervescent matrix tablets of ciprofloxacin HCl (CIPRO). Tablets were prepared by direct compression using HPMC K4M and Carbopol 971P as hydrophilic-controlled release polymers, sodium bicarbonate (NaHCO₃) as gas-generating agent, polypolsdone XL, Explotab and Ac-Di-Sol as swelling agents. Tablets were evaluated for normal and modified initial in vitro floating behavior, floating duration, swelling behavior and in vitro drug release studies. A modified buoyancy lag time for tablets was determined in order to include the effect of bioadhesion on initial buoyancy. The initial buoyancy was found dependent on bioadhesion ability of tablets. The lowest modified buoyancy lag time of 20 seconds was obtained for Formulation F7 having both NaHCO₃ and polyplasdone XL. The floating duration was also found dependent on concentration of NaHCO₃ and swelling agents. The drug release of F7 was also sustained up to 12-hr duration with anomalous drug transport mechanism.

Key words: Bioadhesion, effervescent matrix tablets, gastroretention, modified buoyancy lag time, swelling agents

INTRODUCTION
The drug delivery inside gastric region is a suitable approach for drugs, preferentially absorbed through upper part of gastric region. Sustained drug release for longer duration can also be achieved within gastric region. Several approaches have been successfully utilized for sustained drug delivery inside gastric environment. Floating tablets,[4] multiunit systems,[5] void assemblage system,[6] bioadhesive tablets,[7] swellable systems,[8] etc. are some example of dosage forms developed for drug release within gastric region. The floating matrix tablets may be effervescent[9] or non-effervescent in nature. Non-effervescent floating matrix tablets contain low density excipients like propylene foam powder and aerosol.[10] The presence of sodium bicarbonates (NaHCO₃) in effervescent tablets leads to carbon dioxide bubbles formation which provides buoyancy to matrix tablets. The floating behavior of tablets can be determined by both in vitro and in vivo methods. Both initial buoyancy and long-term buoyancy were important in case of sustained release floating systems. Generally authors utilized buoyancy lag time as an indicator for initial in vitro buoyancy behavior and floating duration (FD) for long-term in vitro buoyancy behavior. In addition to floating behavior the bioadhesion of hydrophilic polymer was also found responsible for gastro retention. Earlier, researcher separately determined buoyancy lag time value and bioadhesion nature of tablets.[11] In this work, we modified the buoyancy lag time determination experiment in order to study the impact of bioadhesion on initial buoyancy of dosage form. The ciprofloxacin HCL (CIPRO) was selected as model drug. CIPRO is well absorbed from proximal part of gastrointestinal tract and due to its short half life (4 hr) it is suitable for once daily administration.[11]

MATERIALS AND METHODS
Ciprofloxacin HCl and HPMC K4M were obtained as gift sample from Sanjivani Parenteral Ltd. Selaquai, Dehradun.
Polyplasdone XL (crospovidone), explotab (sodium starch glycolate), Ac-Di-Sol (croscarmellose sodium) were obtained as gift sample from GlaxoSmithKline Pharmaceuticals Ltd., Nasik, India. Carbopol 971P, PVP K30, Talc and NaHCO₃ were purchased from Central drug house (CDH Ltd.), India.

Preparation of Matrix Tablets
CIPRO and other excipients [Tables 1 and 2] were mixed in a double cone mixer for 5 min. Magnesium stearate (0.5%) was added into previous mixture as lubricant and blended for another 2 min. Tablets were prepared by direct compression using 12-mm flat-faced punch on a sixteen station single rotary compression machine (Cadmach Machinery Co. Pvt. Ltd., Ahmedabad, India). The hardness of different tablets was kept constant at 5 kg/cm² using thickness adjustment and measured by a Monsanto hardness tester (Rimek, Mumbai, India).

Initial In vitro Floating Behavior
Normal buoyancy lag time
In vitro floating behavior of floating matrix tablets was performed in a 1000-ml beaker having 900 ml of 0.1 N HCl. Normal buoyancy lag time (NBLT) was the time taken by tablets to reach the surface of release medium.

Modified buoyancy lag time
Concentrated slurry of agar (20% w/w) in 0.1 N HCl was prepared. The appropriate quantity of slurry was poured in petri dish. The agar petri dish was further dried in hot air oven to allow agar to adhere with glass petri dish. Experiment was performed in 1000 ml. Beaker having 900 ml of 0.1 N HCl. Agar dish was placed at the bottom of beaker. When tablet placed in beaker, it dipped initially toward the bottom and interacts with agar dish. Tablets were tried to detach from agar dish and headed toward surface of release medium [Figure 1]. In this whole process the time taken by tablet to reach at the surface was recorded as the Modified buoyancy lag time (MBLT).

Floating Duration
Tablet was placed into a 1000 ml beaker filled with 900-ml 0.1 N HCl. The duration for which tablet constantly remained buoyant was recorded as floating duration.

Swelling Ability
The swelling behavior of tablets was determined in USP XXVI dissolution apparatus II (Lab India Disso 2000) filled with 900 ml 0.1 N HCl at 37± 0.5°C and 50 rpm. The tablets were removed at regular time interval and excess liquid was removed with help of filter paper. Then weight of swollen tablet was recorded and swelling index was calculated using given formula:[8,11]

Swelling index = \( \frac{W_2 - W_1}{W_1} \)  \( (1) \)

\( W_1 \) – initial weight; \( W_2 \) – weight after given time interval.

![Figure 1: Photographs of formulation F3 showing MBLT in 0.1 N HCL at different time intervals (a) 30 sec (b) 35 sec (c) 40 sec (d) 45 sec](image)

| Table 1: Composition of various matrix tablets |
|---------------------------------------------|
| F1  | F2  | F3  | F4  | F5  | F6  | F7  | F8  | F9  | F10 | F11 | F12 | F13 | F14 |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| CIPRO (mg) | 291 | 291 | 291 | 291 | 291 | 291 | 291 | 291 | 291 | 291 | 291 | 291 | 291 |
| HPMC K4M (mg) | 280 | 280 | 280 | 280 | 280 | 280 | 280 | 280 | 280 | 240 | 200 |
| Sodium bicarbonate (mg) | 35 | 47 | 60 | 35 | 35 | 35 | 35 | 35 | 35 | 35 | 35 | 35 | 35 |
| Polyplasdone XL (mg) | 20 | 40 | 40 | 60 | 40 | 40 | 60 | 40 | 40 | 60 | 40 | 60 | 40 |
| Explotab (mg) | | | | | | | | | | | | | |
| Ac-Di-Sol (mg) | 40 | 40 | 40 |
| Carbopol (mg) | 280 | 280 | 240 |
| Talc (mg) | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Table 2: Floating behaviour of different formulations

|       | NBLT (min) | MBLT (min) | FD (hr) |
|-------|------------|------------|---------|
| F1    | 120 ± 8    | 210 ± 10   | -       |
| F2    | <0.25      | 2 ± 0.16   | 7       |
| F3    | <0.25      | 0.75 ± 0.05| 9.5     |
| F4    | <0.25      | 0.42 ± 0.05| >12     |
| F5    | <0.25      | 1 ± 0.10   | 8.3     |
| F6    | <0.25      | 0.66 ± 0.04| 11      |
| F7    | <0.25      | 0.33 ± 0.05| >12     |
| F8    | <0.25      | 1.66 ± 0.12| 9.5     |
| F9    | <0.25      | 1.33 ± 0.08| 8.5     |
| F10   | <0.25      | 1.5 ± 0.05 | 7.2     |
| F11   | <0.25      | 1.16 ± 0.05| 4       |
| F12   | <0.25      | 4 ± 0.11   | 6.9     |
| F13   | <0.25      | 2 ± 0.05   | 10      |
| F14   | <0.25      | 1.5 ± 0.05 | 8       |

NBLT: Normal buoyancy lag time; MBLT: Modified buoyancy lag time

**In vitro Drug Release**

In vitro drug release studies of the prepared matrix floating tablets were conducted in a USP XXVI dissolution apparatus II (Lab India Disso 2000) filled with 900 ml 0.1 N HCl at 37 ± 0.5°C and 100 rpm. Aliquot of 5 ml were withdrawn from dissolution medium at predetermined time intervals of 1, 2, 4, 6, 8 and 12 hr and 5 ml of fresh medium were replaced with every withdrawal. The samples were analyzed by a UV spectrophotometer (Shimadzu UV-250 1PC double beam) at 278 nm, after filtration and appropriate dilution (y = 0.12x + 0.001; r² = 0.999).

**Drug Release Kinetics**

All the drug release data were fitted for zero-order, first-order, Higuchi model and Koresmeyer-Peppas model with help of PCP-Disso V3.0 software. The Koresmeyer-Peppas equation was utilized for determination of drug release mechanism:[12]

\[
\frac{M_t}{M_\infty} = k t^n
\]  

Where, \( M_t/M_\infty \) is fraction of drug release, \( t \) is time, \( k \) is the constant incorporating structural and geometrical characteristics of dosage form and \( n \) is release exponent. The drug release mechanism was determined by calculating value of \( n \) for the portion of drug release curve where value of fraction of drug release \( (M_t/M_\infty) \) was equal or less than 0.6.[13]

**RESULTS AND DISCUSSION**

**In vitro Floating Behavior**

In present study we modified initial in vitro buoyancy determination experiment in order to include the effect of bioadhesion on initial buoyancy of tablets. The modified BLT value reflected initial buoyancy behavior of tablets with considering their bioadhesion ability.
The MBLT values for explotab and Ac-Di-sol (F8 and F9) were higher in comparison to polyplasdone XL-containing tablets [Figure 3]. This difference might be due to different swelling mechanism of swelling agents.\cite{15} Polyplasdone XL is having rapid expansion ability due to wicking mechanism whereas Explotab and Ac-Di-sol were having slow expansion due to swelling mechanism.\cite{16} Further the concentration of polyplasdone XL was varied from 20 to 60 mg (F5-F7). As the concentration of polyplasdone XL was increased, the MBLT values were also reduced. Early detachment of matrix tablet from agar plate was obtained at higher proportion of polyplasdone XL.

Again polyplasdone XL containing tablets were remained afloat for longer duration in comparison to other swelling agents. The FD of matrix tablets increased with increase in proportion of swelling agents.

**Effect of Hydrophilic Polymer on In vitro Floating Behavior**

Two different hydrophilic polymers were utilized to develop floating matrix tablets. The hydrophilic polymer chains swelled on contact with release medium and form swollen gel matrix.\cite{17} The CO\textsubscript{2} bubbles and swollen particles of swelling agents were get entrapped inside gel matrix of hydrophilic polymer and as a result the density reduction of matrix tablets provided buoyancy to matrix tablets.

Tablets containing HPMC K4M achieved lower MBLT values in comparison to carbopol-containing tablets. Although very little difference was observed between NBLT values of HPMC K4M and carbopol formulation but difference between MBLT values was more. This certainly was due to higher bioadhesion efficiency of carbopol in comparison to HPMC K4M.\cite{18} Thus more time was required to detach the carbopol containing tablets from agar plates.

Further reduction in proportion of hydrophilic polymer (F6, F10 and F11) resulted in lower MBLT value but tablets integrity was also affected. The FD was also reduced with reduction in proportion of hydrophilic polymer.

At low concentration (F11) of hydrophilic polymer the resulted swollen gel might not able to hold CO\textsubscript{2} bubbles and swelling agent particles and tablets lost integrity within 4 hrs.

**Swelling Behavior**

The maximum swelling index for F1 was achieved after 5 hrs. Viridéna \textit{et al.}\cite{19} suggested that the diffusion of water into glassy HPMC chains reduces its glass transition temperature, \textit{T}_g. Due to reduction in \textit{T}_g, the glassy polymer converted into rubbery form. Further diffusion of water resulted in expansion of rubbery HPMC matrix and swelling occurs. After reaching a specific maximum swelling the erosion of hydrophilic chains occurs due to polymer chain relaxation.\cite{20}

Increase in swelling indices were observed with the formulations (F2, F3 and F4) containing SB [Figure 4]. The maximum swelling indices for these formulations were obtained in 4 hrs.

The rapid bubble formation was responsible for rapid volume expansion of SB containing formulations. The erosion tendency of SB containing formulations was also higher in comparison to F1.

Further, more increase in swelling was observed with matrix formulation having swelling agents [Figure 5]. For swelling agents containing tablets, maximum swelling indices were observed within 3 hrs. Out of three different swelling agents, highest swelling indices were obtained for polyplasdone XL-containing matrix tablets. Both wicking and swelling of polyplasdone XL particles might be responsible for higher swelling indices of tablets. Again maximum swelling was followed by erosion of matrix due to polymeric chain relaxations as swelling agent particles detached from matrix.

In comparison to HPMC K4M formulations, the maximum swelling index for carbopol containing tablets (F13, F14) were achieved after 4 hr. [Figure 6]. Rapid hydration of carbopol might be responsible for this behavior.
In vitro Drug Release Studies
The high viscosity of hydrophilic polymeric chains is responsible for high viscosity gel formation and subsequently drug release retardation.[21,22] At 200 mg concentration of HPMC (F11), the complete drug release was achieved within 8 hrs. With 280 mg concentration (F9) of HPMC, the drug release was further sustained up to 12 hrs [Figure 7a]. Similar pattern of drug release reduction was observed with increase in carbopol concentration [Figure 7d].

The presence of gas-generating agent was further increased the drug release rate from matrix tablets of HPMC K4M. The effect of the SB on the release of the drug from the tablets in 0.1N HCl (pH 1.2) is shown in [Figure 7b]. Increase in concentration of SB was also resulted in increase in drug release rate from matrix tablets. At high concentration of SB (F4), the formation of more effervescence would leads to the faster hydration of matrix and consequently rapid drug release rate.

High initial burst effect was observed with formulations having swelling agents in comparison to other formulations [Figure 7]. The swelling tendency of super-disintegrants might be responsible for this high initial burst drug release. Later, slow drug release was observed due to formation of swollen gel matrix. As the time progress the hydration of polymeric chains leads to gel formation and subsequently entrapped the swollen particles of swelling agents. Also, the drug release rate from matrix tablets was increased with the increase in concentration of polyplasdone XL.

The drug release data was further subjected to the various models to get the information about the drug release kinetics. The release data was treated with zero order, first order, Higuchi model and Koresmeyer-Peppas (KP) model. The best model was selected according to highest

![Figure 4: Swelling patterns of matrix tablets with change in SB concentration (mean ± SD, n = 3)](image)

![Figure 5: Swelling patterns of matrix tablets with change in swelling agent concentration (mean ± SD, n = 3)](image)

Table 3: $R^2$ for different release kinetics models with $n$ for various matrix tablets

| Formulation code | Zero order $R^2$ | First order $R^3$ | Higuchi Model $R^2$ | Koresmeyer-Peppas $R^2$ | n |
|------------------|-----------------|------------------|---------------------|------------------------|---|
| F1               | 0.996           | 0.903            | 0.991               | 0.997                  | 0.782 |
| F2               | 0.997           | 0.915            | 0.956               | 0.999                  | 0.874 |
| F3               | 0.994           | 0.883            | 0.963               | 0.998                  | 0.78  |
| F4               | 0.995           | 0.745            | 0.976               | 0.999                  | 0.73  |
| F5               | 0.991           | 0.892            | 0.983               | 0.995                  | 0.589 |
| F6               | 0.993           | 0.912            | 0.979               | 0.997                  | 0.592 |
| F7               | 0.986           | 0.861            | 0.983               | 0.992                  | 0.564 |
| F8               | 0.984           | 0.932            | 0.963               | 0.998                  | 0.598 |
| F9               | 0.979           | 0.919            | 0.959               | 0.989                  | 0.586 |
| F10              | 0.97            | 0.909            | 0.987               | 0.993                  | 0.567 |
| F11              | 0.802           | 0.957            | 0.931               | 0.95                   | 0.604 |
| F12              | 0.992           | 0.953            | 0.956               | 0.997                  | 0.632 |
| F13              | 0.989           | 0.889            | 0.982               | 0.994                  | 0.596 |
| F14              | 0.96            | 0.923            | 0.984               | 0.992                  | 0.513 |

$R^2$: Regression coefficient; $n$: Diffusion exponent
value of regression coefficient (R²(2)). The release data was best fitted with KP model Table 3. Further the mechanism of drug release was determined by using Ritger-Peppas model (considering Mt/M∞ ≤ 0.6). The value of diffusion constant (n) is shown in table. Because the value of n was found between 0.45-0.89 (anomalous drug transport) thus both diffusion and polymeric chain relaxation were found responsible for drug release.[2324]

CONCLUSIONS

Controlled release effervescent floating matrix tablets of CIPRO were successfully prepared. The initial buoyancy behavior was affected by the bioadhesion nature of matrix tablets. Also, better in vitro MBLT and FD were depends on the proportion of SB and polyplasdone XL in matrix tablets. The drug release was successfully sustained for 12 hr and mechanism of drug release was associated with both swelling and erosion of polymeric chains.

REFERENCES

1. Deshpande AA, Shah NH, Rhodes CT, Malick W. Development of a novel controlled-release system for gastric retention. Pharm Res 1997;14:815-9.
2. Talukder R, Fassihi R. Gastroretentive Delivery Systems: A Mini Review. Drug Dev Ind Pharm 2004;30:1019-28.
3. Arora S, Javed A, Ahuja A, Khar RK, Baboota S. Floating drug delivery system: A review. AAPS PharmSciTech 2006;6:E372-90.
4. Rahman Z, Ali M, Khar R. Design and evaluation of bilayer floating tablets of captopril. Acta Pharm 2006;56:49-57.
5. Sriamornsak P, Sunthongjeen S, Puttipipatkhachorn S. Use of pectin as a carrier for intragastric floating drug delivery: Carbonate salt contained beads. Carbohydrate Polymers 2007;67:436-45.
6. Strusi OL, Sonvico F, Bettini R, Santi P, Colombo G, Barata P, et al. Module assemblage technology for floating systems: in vitro flotation and in vivo gastro-retention. J Control Release 2008;129:88-92.
7. Chavanpatil M, Jain P, Chaudhari S, Shear R, Vavia P. Development of sustained release gastroretentive drug delivery system for ofloxacin: In-vitro and in-vivo evaluation. Int J Pharm 2005;304:178-84.
8. Adhikary A, Vavia PR. Bioadhesive ranitidine hydrochloride for gastroretention with controlled microenvironmental Ph. Drug Dev Ind Pharm 2008;34:860-9.
9. Gutiérrez-Sánchez PE, Hernández-León A, Villafuerte-Robles L. Effect of sodium bicarbonate on the properties of metronidazole floating matrix tablets. Drug Dev Ind Pharm 2008;34:171-80.
10. Streubel A, Siepmann J, Bodmeier R. Floating matrix tablets based on low density foam powder: Effects of formulation and processing parameters on drug release. Eur J Pharm Sci 2003;12:37-45.
11. Tadros MI. Controlled-release effervescent floating matrix tablets of ciprofloxacin hydrochloride: Development, optimization and
in vitro–in vivo evaluation in healthy human volunteers. Eur J Pharm Biopharm 2010;74:332-9.

12. Ritger PL, Peppas NA. A simple equation for description of solute release. I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Release 1987;5:23-36.

13. Ritger PL, Peppas NA. A simple equation for description of solute release. II. Fickian and anomalous release from swellable devices. J Control Release 1987;5:37-42.

14. Colombo P, Bettini R, Santi P, De Ascentiis A, Peppas NA. Analysis of the swelling and release mechanisms from drug delivery systems with emphasis on drug solubility and water transport. J Control Release 1996;39:231-7.

15. Arza RA, Gonugunta CS, Veerareddy PR. Formulation and Evaluation of Swellable and Floating Gastroretentive Ciprofloxacin Hydrochloride Tablets. AAPS PharmSciTech 2009;10:1220-6.

16. Kornblum SS, Stoopak SB. A new tablet disintegrating agent: Cross-linked polyvinylpyrrolidone. J Pharm Sci 1973;62:43-9.

17. Colombo P, Bettini R, M’aximo G, Catellani PL, Santi P, Peppas NA. Drug diffusion front movement is important in drug release control from swellable matrix tablets. J Pharm Sci 1995;84:991-7.

18. Sheskey PJ, Rowe RC, Weller PJ. Handbook of Pharmaceutical Excipients. London: PhP pharmaceutical press; 6th ed. 2009. p. 110-3.

19. Viridéna A, Wittgren B, Larsson A. Investigation of critical polymer properties for polymer release and swelling of HPMC matrix tablets. Eur J Pharm Sci 2009;36:297-309.

20. Zeng A, Yuan B, Fu Q, Wang C, ZhaoG. Influence of sodium dodecyl sulfate on swelling, erosion and release behavior of HPMC matrix tablets containing a poorly water-soluble drug. Pharm Dev Technol 2009;14:499-505.

21. Swain K, Pattnaik S, Mallick S, Chowdary KA. Influence of hydroxypropyl methylcellulose on drug release pattern of a gastroretentive floating drug delivery system using a 3² full factorial design. Pharm Dev Technol 2009;14:193-8.

22. Colombo P, Santi P, Bettini R, Brazel CS, Peppas NA. Drug Release from Swelling-Controlled Systems. In: Wise DL. Editor. Handbook of Pharmaceutical Controlled Release Technology. New York: Marcel Dekker Inc; 2000. p. 190.

23. Lee PI. Diffusional release of a solute from a polymeric matrix: approximate analytical solutions. J Membrane Sci 1980;7:255-75.

24. Harland RS, Gazzaniga A, Sangalli ME, Colombo P, Peppas NA. Drug/polymer matrix swelling and dissolution. Pharm Res 1988;5:488-94.

How to cite this article: Negi JS, Trivedi A, Khanduri P, Negi V, Kasliwal N. Effect of bioadhesion on initial in vitro buoyancy of effervescent floating matrix tablets of ciprofloxacin HCL. J Adv Pharm Tech Res 2011;2:121-7.

Source of Support: Nil, Conflict of Interest: Nil.